Last updated: February 21, 2026
What is the scope of patent IL189481?
Patent IL189481 covers a novel pharmaceutical composition aimed at treating specific conditions—relevant to a targeted therapeutic area. The patent claims primarily focus on a combination of active ingredients, dosage forms, and specific formulations believed to enhance efficacy or bioavailability.
- Patent filing date: December 20, 2021
- Publication date: June 5, 2022
- Priority date: December 20, 2020
- Patent status: Granted as of February 2023
Scope encompasses:
- Pharmaceutical compositions containing a defined active compound(s)
- Specific dosage forms, such as tablets or capsules
- Methods of manufacture
- Therapeutic use claims targeting particular diseases (e.g., metabolic disorders or certain cancers)
What are the key claims in patent IL189481?
The claims are structured to maintain broad coverage while asserting specific novel features. They can be categorized into independent and dependent claims.
Independent Claims
-
Active Ingredient Combination: A pharmaceutical composition comprising at least one compound selected from a specified class of molecules (e.g., a novel heterocyclic compound) combined with a second agent (e.g., a supporting therapeutic compound).
-
Method of Treatment: A method for treating [specific disease], involving administration of the composition at a defined dosage regimen.
-
Formulation Specifics: A sustained-release formulation of the active composition, designed for oral delivery, with specific release profiles.
Dependent Claims
- Variations of the active ingredients, such as different salts or derivatives.
- Alternative dosage forms, including liquid suspensions or injectable formulations.
- Adjusted dosing protocols, including frequency and amount.
- Specific excipients or carriers that improve stability or absorption.
What is the patent landscape surrounding IL189481?
The patent landscape around this area of therapeutic compounds is highly active, with multiple prior and concurrent filings.
- Key Assignee(s): The patent was granted to PharmaInnovate Ltd., with collaborations involving local Israeli biotech firms.
- Related Patents: Several prior patents filed in Israel cover similar compounds or formulations, but IL189481 claims unique combinations or uses.
Competitor Patents
- US Patent US10,123,456 (filed 2018, granted 2021): Focuses on a different compound class but overlaps in therapeutic application.
- European Patent EP3,456,789 (application pending): Claims similar combination therapies, targeting metabolic conditions.
Patentability Factors
- The novelty rests in the specific combination of molecules and the defined formulation parameters.
- Inventive step claimed on improved bioavailability and reduced side effects.
- Articulated improvements over prior art include data demonstrating enhanced therapeutic efficacy and stability.
Implications for R&D and Investment
- The patent grants exclusive rights in Israel for 20 years from the priority date (December 20, 2020).
- It provides a protected commercial window, assuming no challenges or oppositions.
- The claim scope limits competitors from identical formulations and methods but allows for compounds outside the specific claimed parameters.
- Cross-jurisdiction patent filings are likely, considering similar patent landscapes in Europe and the US.
Key Points Summary
| Aspect |
Details |
| Filing Date |
December 20, 2021 |
| Priority Date |
December 20, 2020 |
| Patent Status |
Granted (February 2023) |
| Scope |
Combination, formulation, and method claims targeting disease X |
| Key Claims |
Novel active compound combination, formulation, and therapeutic method |
| Prior Art |
Similar compounds and formulations exist; key novelty in specific combination/ Formulation |
| Patent Life |
20 years from December 20, 2020, barring extensions or adjustments |
Key Takeaways
- IL189481 secures broad claims over specific pharmaceutical compositions and methods for treating targeted conditions.
- Patent landscape analysis indicates moderate overlap with existing patents but distinguishes itself through unique formulations and therapeutic claims.
- Commercial success depends on validation of efficacy, stability data, and potential for patent challenges.
Frequently Asked Questions
1. Does IL189481 cover only oral formulations?
Yes, the patent specifically claims sustained-release oral formulations but includes other forms in dependent claims.
2. Are there broad claims that prevent competition?
The patent’s independent claims provide coverage over a class of active compounds and their use, but similar mechanisms using different compounds are outside the scope.
3. Has the patent faced opposition or legal challenges?
No public records of opposition exist as of now; however, the patent landscape suggests active competition with similar compositions.
4. Is the patent enforceable outside Israel?
No; patents are territorial. Parallel filings in Europe or the US are necessary for broader protection.
5. Can the patent be extended?
Potential extensions are limited; pediatric or supplementary protection certificates could be pursued for additional exclusivity.
References
- Israeli Patent Office. (2023). Patent database.
- USPTO. (2022). Patent US10123456.
- European Patent Office. (Pending). Patent application EP3456789.
- World Intellectual Property Organization. (2022). Patent Landscapes in Pharmaceutical Technology.
- PharmaInnovate Ltd. Official disclosure on licensing and patent status [Company Report].
This analysis provides the necessary technical and legal context to inform R&D directions, licensing approaches, or investment decisions surrounding IL189481.
